Other Products was Amphastar Pharmaceuticals’s largest segment in fiscal 2025, bringing in $229.65M of $719.89M (32%).
| Subsegments | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Other Products | $121.89M | $250.42M | $225.64M | $229.65M |
| Baqsimi | — | — | $126.90M | $185.36M |
| Primatene Mist | $84.31M | $89.32M | $102.01M | $108.67M |
| Glucagon | $55.32M | $113.68M | $108.32M | $69.08M |
| Epinephrine | $74.20M | $81.65M | $94.09M | $70.64M |
| Lidocaine | $52.54M | $58.16M | $55.85M | $56.48M |
| Phytonadione | $49.50M | — | — | — |
| Other Revenues | — | $51.16M | $19.15M | — |
| Enoxaparin | $34.95M | — | — | — |
| Naloxone | $26.27M | — | — | — |
| Total | $498.99M | $644.40M | $731.97M | $719.89M |
Amphastar Pharmaceuticals brought in $719.89M from its six segments in fiscal 2025, the year ended December 31, 2025. Amphastar Pharmaceuticals regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $731.97M. Other Products was the largest at $229.65M (31.9%), ahead of Baqsimi at $185.36M (25.7%) and Primatene Mist at $108.67M (15.1%). The other three segments brought in $196.21M combined.
Compared with fiscal 2024, Baqsimi grew fastest, up 46.1% to $185.36M, while Glucagon fell the most, down 36.2% to $69.08M.
Amphastar Pharmaceuticals began breaking out Baqsimi in fiscal 2024, when it brought in $126.90M. Amphastar Pharmaceuticals stopped reporting Phytonadione ($49.50M in fiscal 2022), Enoxaparin ($34.95M in fiscal 2022), Naloxone ($26.27M in fiscal 2022) and one other as separate segments.
United States was Amphastar Pharmaceuticals’s largest region in fiscal 2025, bringing in $681.42M of $719.89M (95%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $486.83M | $635.19M | $707.68M | $681.42M | ||||||||||
| France | $7.46M | $4.70M | $19.95M | $35.28M | ||||||||||
| China | $4.70M | $4.51M | $4.34M | $3.18M | ||||||||||
| Total | $498.99M | $644.40M | $731.97M | $719.89M |
Amphastar Pharmaceuticals brought in $719.89M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 1.7% from $731.97M in fiscal 2024. United States was the largest at $681.42M (94.7%), ahead of France at $35.28M (4.9%) and China at $3.18M (0.4%).
Compared with fiscal 2024, France grew 76.9% to $35.28M, while United States fell 3.7% to $681.42M. From fiscal 2022 to 2025, combined revenue from these regions grew from $498.99M to $719.89M, a compound annual growth rate of 13.0%. United States' share of the total fell from 97.6% to 94.7%.
Product was Amphastar Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $719.89M of $723.09M (100%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Product | $498.99M | $593.24M | $712.81M | $719.89M | |
| Product Revenues, Net | — | — | — | — | |
| Other | — | $51.16M | $19.15M | — | |
| Research & Development Services | $4.30M | $4.50M | $4.20M | $3.20M | |
| Total | $503.29M | $648.90M | $736.17M | $723.09M |
Amphastar Pharmaceuticals brought in $723.09M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Amphastar Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $736.17M. Product was the largest at $719.89M (99.6%), ahead of Research & Development Services at $3.20M (0.4%).
From fiscal 2022 to 2025, combined revenue from these lines grew from $503.29M to $723.09M, a compound annual growth rate of 12.8%. Product's share held steady at about 99.6%.
Amphastar Pharmaceuticals stopped reporting Other as a separate line after fiscal 2024, when it brought in $19.15M.
Amphastar Pharmaceuticals (AMPH) reports its revenue by subsegments, by geography and by product and service. In fiscal 2025, Other Products was its largest segment, bringing in $229.65M (31.9% of the total), followed by Baqsimi at $185.36M (25.7%).
Other Products was Amphastar Pharmaceuticals' largest segment in fiscal 2025, bringing in $229.65M, or 31.9% of the $719.89M total across its six segments.
United States was Amphastar Pharmaceuticals' largest region in fiscal 2025, bringing in $681.42M, or 94.7% of the $719.89M total across its three regions.
Product was Amphastar Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $719.89M, or 99.6% of the $723.09M total across its two product and service lines.
France grew faster than United States in fiscal 2025, up 76.9% from $19.95M to $35.28M. United States fell 3.7% to $681.42M.
Every figure comes from Amphastar Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Amphastar Pharmaceuticals gives it, and years follow its fiscal calendar.
Amphastar Pharmaceuticals' revenue by subsegments goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.